The global Irritable Bowel Syndrome Treatment Market is estimated to be valued at US$ 1,444.7 million in 2022 and is expected to exhibit a CAGR of 13.2% during the forecast period (2022-2030).
The Irritable Bowel Syndrome Treatment Market data for treating Irritable Bowel Syndrome has been segmented by drug type into lubiprostone, linaclotide, rifaximin, eluxadoline, and alosetron. In 2022, the linaclotide category dominated the market. From 2022 to 2030, it is anticipated to increase at a higher rate. Increased generic linaclotide production and greater market consolidation for creating and marketing linaclotide as a treatment for IBS are credited with the segment's rise. Due to its effectiveness in treating chronic constipation and irritable bowel syndrome with constipation (IBS-C), conditions that were previously unmet by conventional methods, linaclotide is in great demand. Over the anticipated time, the demand will probably rise due to its increasing acceptance rate. The expansion of Irritable Bowel Syndrome Treatment Market is driven by the medicine linaclotide's efficacy in comparison to other pharmaceuticals of a similar class available on the market.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/03/the-global-irritable-bowel-syndrome.html
